Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
54.48
+0.46 (0.85%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Monopar Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -13.72 | -15.59 | -8.4 | -10.52 | -9.1 | |
| Loss (Gain) From Sale of Investments | -0.72 | -0.01 | - | - | - | |
| Stock-Based Compensation | 4.84 | 1.14 | 1.9 | 1.64 | 1.47 | |
| Other Operating Activities | - | 4.55 | - | - | - | |
| Change in Accounts Payable | 0.39 | 0.51 | -1.33 | 1.48 | 0.4 | |
| Change in Other Net Operating Assets | -2.99 | 2.99 | -0.02 | 0.17 | -0.09 | |
| Operating Cash Flow | -12.2 | -6.4 | -7.86 | -7.23 | -7.32 | |
| Investment in Securities | -63.45 | -14.34 | 4.93 | -4.92 | - | |
| Investing Cash Flow | -63.45 | -14.34 | 4.93 | -4.92 | - | |
| Issuance of Common Stock | 127.71 | 59.4 | 2.07 | 0.11 | 11.28 | |
| Repurchase of Common Stock | -36.13 | -0.1 | -0.05 | -0.08 | -0.06 | |
| Other Financing Activities | - | - | - | - | -0.34 | |
| Financing Cash Flow | 91.57 | 59.29 | 2.03 | 0.03 | 10.88 | |
| Foreign Exchange Rate Adjustments | 0.1 | 0 | -0.02 | -0 | 0 | |
| Net Cash Flow | 16.02 | 38.55 | -0.92 | -12.12 | 3.57 | |
| Levered Free Cash Flow | -8.2 | -5.48 | -5.01 | -3.22 | -3.99 | |
| Unlevered Free Cash Flow | -8.2 | -5.48 | -5.01 | -3.22 | -3.99 | |
| Change in Working Capital | -2.61 | 3.5 | -1.35 | 1.65 | 0.32 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.